Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15836429 | 0.85 | PTGS2 (0.53) | PTGS2ENPP2PSIP1CA2CA1 | |
| SCHEMBL648284 | 0.82 | TSHR (0.43) | CA2CA1 | |
| SCHEMBL22089501 | 0.76 | TSHR (0.48) | CA2CA1CA12CA9CA7 | |
| SCHEMBL5522736 | 0.76 | PTGS2 (0.70) | PTGS2ENPP2PTGS1CA2CA1 | |
| SCHEMBL9815686 | 0.76 | PTPN2 (0.36) | CA2CA1 | |
| SCHEMBL5599359 | 0.76 | NAAA (0.42) | CA2CA1 | |
| SCHEMBL3850384 | 0.75 | PTGS2 (0.50) | PTGS2ENPP2CA2CA1CA12 | |
| SCHEMBL6480783 | 0.75 | CA12 (0.68) | PTGS2ENPP2CA2CA1CA12 | |
| SCHEMBL6793165 | 0.74 | CA2 (0.67) | PTGS2ENPP2CA2 | |
| SCHEMBL7838626 | 0.74 | AGXT (0.52) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807693-B2 | Apelin polypeptides | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20170107255-A1 | APELIN POLYPEPTIDES | AMGEN INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20160067347-A1 | APJ RECEPTOR AGONISTS AND USES THEREOF | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107255-A1 | APELIN POLYPEPTIDES | APLNR, FABP3, AP3B1 | PTGS2 3850/4885ENPP2 65/4885PTGS1 3535/4885 |
| US-11807693-B2 | Apelin polypeptides | APLNR, FABP3, AP3B1 | PTGS2 3850/4885ENPP2 65/4885PTGS1 3535/4885 |
| US-20160067347-A1 | APJ RECEPTOR AGONISTS AND USES THEREOF | APLNR, FABP3, AP2B1 | PTGS2 2546/4885ENPP2 26/4885PTGS1 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.